(NASDAQ: ACLX) Arcellx's forecast annual revenue growth rate of 172.22% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Arcellx's revenue in 2026 is $22,286,000.On average, 18 Wall Street analysts forecast ACLX's revenue for 2026 to be $6,484,241,555, with the lowest ACLX revenue forecast at $1,719,306,473, and the highest ACLX revenue forecast at $17,645,698,473. On average, 16 Wall Street analysts forecast ACLX's revenue for 2027 to be $14,463,811,902, with the lowest ACLX revenue forecast at $6,991,846,323, and the highest ACLX revenue forecast at $20,312,377,900.
In 2028, ACLX is forecast to generate $27,190,773,388 in revenue, with the lowest revenue forecast at $15,187,207,176 and the highest revenue forecast at $38,438,780,428.